BTIG Reiterates Buy on Theravance Biopharma, Maintains $21 Price Target

BTIG analyst Julian Harrison has reiterated a Buy rating on Theravance Biopharma (NASDAQ: TBPH) and has maintained a price target of $21 for the stock. No additional financial figures or strategic changes were mentioned in the article.